The experience of key technical personnel who will be responsible for the day-to-day operation: Meharry Principal Investigator: Billy R. Ballard, DDS, MD, is board-certified pathologist. Professor and Chair of the Department of Pathology at Meharry Medical College. Dr. Ballard has more than 40 years experience as a general surgical and cytopathologist with special interest and experts in head and neck, genitourinary, breast, gynecologic, and soft tissue pathology. Dr. Ballard will be responsible for refining the laboratory procedures, hiring personnel, managing the budget, evaluafing and selecting equipment for the laboratory. In addition. Dr. Ballard will be responsible for ensuring the laboratory meets the needs of Partnership investigators. This will be accomplished by interacting closely with the Histopathology Core Internal and External Advisory Committees, which has the responsibility for oversight ofthe core and with the Human Tissue Acquisition and Pathology Core at VICC. The oversight committees will assist with the development and implementation of operational policies and procedures for the core including the development of fee schedules, development and implementation of new procedures or tests, the prioritization and allocation of banked samples, and the selection of pilot studies that to receive fee weavers or a reducfion, and others as the need arises. A close working relationship will be established and maintained to assure that we address the needs of the investigators ufilizing services of the core. An addifional responsibility shall include interacting with principle investigators in developing specific tissue collection protocols available for any technical or scienfific questions concerning tissue procurement. He is responsible for Increasing awareness and availability of this Core the Partnership research community by giving a series of seminars to various groups concerning operafion and services.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Meharry Medical College
United States
Zip Code
Umeukeje, Ebele M; Wild, Marcus G; Maripuri, Saugar et al. (2018) Black Americans' Perspectives of Barriers and Facilitators of Community Screening for Kidney Disease. Clin J Am Soc Nephrol 13:551-559
Vercruysse, Koen; Clark, Astiney; Alatas, Noor et al. (2018) Polysaccharide-mediated synthesis of melanins from serotonin and other 5-hydroxy indoles. Future Sci OA 4:FSO280
Hull, P C; Buchowski, M; Canedo, J R et al. (2018) Childhood obesity prevention cluster randomized trial for Hispanic families: outcomes of the healthy families study. Pediatr Obes 13:686-696
Sanderson, Maureen; Aldrich, Melinda C; Levine, Robert S et al. (2018) Neighbourhood deprivation and lung cancer risk: a nested case-control study in the USA. BMJ Open 8:e021059
Ochieng, Josiah; Nangami, Gladys; Sakwe, Amos et al. (2018) Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes. Int J Mol Sci 19:
Tantawy, Mohammed N; Charles Manning, H; Peterson, Todd E et al. (2018) Translocator Protein PET Imaging in a Preclinical Prostate Cancer Model. Mol Imaging Biol 20:200-204
Burroughs, Andrea Flores; Eluhu, Sylvia; Whalen, Diva et al. (2018) PML-Nuclear Bodies Regulate the Stability of the Fusion Protein Dendra2-Nrf2 in the Nucleus. Cell Physiol Biochem 47:800-816
Ignacio, Rosa Mistica C; Lee, Eun-Sook; Wilson, Andrew J et al. (2018) Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer. Immune Netw 18:e29
Wilkins, Consuelo H (2018) Putting The Person In Personalized Medicine Personalized Medicine: Empowered Patients In The 21st Century? By Barbara Prainsack New York (NY) : NYU Press , 2017 288 pp., $30. Health Aff (Millwood) 37:823-824
Ignacio, Rosa Mistica C; Dong, Yuan-Lin; Kabir, Syeda M et al. (2018) CXCR2 is a negative regulator of p21 in p53-dependent and independent manner via Akt-mediated Mdm2 in ovarian cancer. Oncotarget 9:9751-9765

Showing the most recent 10 out of 178 publications